Most Popular
-
1
[Exclusive] Korean military set to ban iPhones over 'security' concerns
![[Exclusive] Korean military set to ban iPhones over 'security' concerns](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050599_0.jpg&u=20240423183955)
-
2
Korean, Romanian leaders discuss defense tech, nuclear energy
-
3
S. Korea calls on Japan to confront history amid Yasukuni Shrine visit
-
4
Yoon’s jailed mother-in-law excluded from latest parole list
-
5
Hybe and Min Hee-jin, CEO of Hybe sublabel Ador, lock horns
![[Exclusive] Korean military set to ban iPhones over 'security' concerns](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050599_0.jpg&u=20240423183955)
-
6
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
7
Korea’s homegrown nanosatellite successfully launches into space
-
8
[Pressure points] Leggings in public: Fashion statement or social faux pas?
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
-
9
Nicaragua shuts down Seoul embassy
-
10
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
![[Pressure points] Leggings in public: Fashion statement or social faux pas?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/23/20240423050669_0.jpg&u=)
GeneOne Life Science wins EMA nod for phase 2 clinical study of COVID-19 treatment
By Shim Woo-hyunPublished : Nov. 1, 2021 - 16:33
GeneOne Life Science’s investigational oral drug for COVID-19 has received regulatory approvals from the European Medicines Agency and Bulgaria to conduct a phase 2 clinical trial in Bulgaria, the Korean biotech firm said Monday.
The Balkan nation is among the five regions where GeneOne Life Science plans to conduct phase 2 studies of GLS-1027. It is also the last of the five to give the company a go-ahead. The four others are the US, South Korea, Puerto Rico and North Macedonia.
GeneOne Life Science plans to confirm GLS-1027’s therapeutic effect on a total of 132 patients infected with COVID-19 and its variants through safety and efficacy tests.
GLS-1027 is being developed as an oral pill that could suppress severe pneumonia caused by COVID-19 infection.
In animal tests, it showed therapeutic effects on pneumonia caused by the coronavirus.
GeneOne Life Science hopes that the drug candidate could also be applied to treat other autoimmune diseases.
-
Articles by Shim Woo-hyun
